{"schema_version":"secwatch.filing_event.v1","accession":"0001520138-24-000105","form_type":"8-K","ticker":"BIVI","cik":"0001580149","company_name":"BIOVIE INC.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.690792+00:00","generated_at":"2026-06-04T23:50:22.541358+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioVie updates pipeline; plans Phase 2b PD trial summer 2024, delays AD Phase 3 to 2025","bullets":["Raised $18.8M net ($21M gross) in equity financing to fund near-term priorities.","Phase 2b monotherapy trial of NE3107 in Parkinson's planned for late summer 2024; 100–150 patients.","Phase 3 Alzheimer's trial postponed to early 2025 to use once-daily NE3107 formulation.","BIV201 Phase 3 in ascites delayed pending partnership; FDA guidance received.","Previous NE3107 data showed 68% slowing on CDR-SB in AD and improved non-motor symptoms in PD."],"urls":{"canonical":"https://secwatch.observer/filing/0001520138-24-000105","json":"https://secwatch.observer/filing/0001520138-24-000105.json","markdown":"https://secwatch.observer/filing/0001520138-24-000105.md","text":"https://secwatch.observer/filing/0001520138-24-000105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/0001520138-24-000105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580149/000152013824000105/bivi-20240311_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:50:22.541358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}